ReviewFrontiers in aging neuroscience2026
Magnetic resonance imaging volumetry in atypical parkinsonism: current evidence and neuroradiological perspectives.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical parkinsonism, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal syndrome (CBS), represents a major diagnostic challenge, particularly in the early stages of disease. Magnetic resonance imaging (MRI) plays a pivotal role in the differential diagnosis of these disorders. Beyond conventional qualitative assessment, quantitative MRI techniques, especially volumetry and planimetry, have gained increasing importance as objective tools for evaluating disease specific patterns of brain atrophy. This narrative review summarizes current evidence on MRI-based morphometric approaches in atypical parkinsonism, with a particular focus on brainstem, basal ganglia, cerebellar, and cortical measurements. The diagnostic value of established indices, including the Magnetic Resonance Parkinsonism Index (MRPI) and its updated version, MRPI 2.0, is discussed, along with advances in automated segmentation and machine learning based approaches. The potential role of MRI volumetry as both a diagnostic and progression biomarker is highlighted, together with current limitations and future perspectives relevant to neuroradiological practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.